|
Mar 28
|
March-ing Forward With Another New Year’s Prediction
|
|
Mar 28
|
Is Bristol Myers Squibb Stock a Buy?
|
|
Mar 28
|
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results
|
|
Mar 27
|
Bristol Myers Squibb (BMY) Rises Higher Than Market: Key Facts
|
|
Mar 27
|
The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio
|
|
Mar 26
|
20 Countries with the Highest Heart Disease Deaths Per Capita
|
|
Mar 26
|
Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes
|
|
Mar 25
|
Bristol-Myers Squibb Company (BMY) Impacted by Delay in New Product Launches
|
|
Mar 25
|
Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio
|
|
Mar 22
|
Bristol-Myers Squibb (NYSE:BMY) Has Announced A Dividend Of $0.60
|
|
Mar 21
|
Bristol Myers Squibb (BMY) Stock Declines While Market Improves: Some Information for Investors
|
|
Mar 21
|
New Blood Thinners Will Prevent Blood Clots Without Causing Bleeding
|
|
Mar 21
|
Bristol Myers (BMY) Gets EC Nod for Abecma's Label Expansion
|
|
Mar 20
|
Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
|
|
Mar 20
|
UPDATE 2-Bristol Myers' Opdivo-Yervoy combo meets main goal in liver cancer trial
|
|
Mar 20
|
Bristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line Treatment of Advanced Hepatocellular Carcinoma
|
|
Mar 19
|
Bristol Myers Squibb and Ted Danson Empower Those with Plaque Psoriasis to Take Action in "SO, Have You Found It?" Campaign
|
|
Mar 18
|
James D. Robinson III, Who Tried to Diversify American Express Far Beyond Cards, Dies at 88
|
|
Mar 18
|
Bristol Myers' (BMY) Abecma Gets ODAC Votes for Label Expansion
|
|
Mar 18
|
Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio
|